Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01012492 · OUTCOME

Protective Immunity

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT · Source last updated 2019-11-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percentage of total CD8+ t-cells
Interval / dispersion
Standard Error
Time frame
Day +365 post-transplant

What was measured

Percent of CMV virus binding CD8+ t-cells at day +365 post-transplant

Groups in this outcome

Abatacept

Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept. Abatacept: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Abatacept10

Reported measurements

Source class 1
Values in percentage of total CD8+ t-cells · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Abatacept2.81.7Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.7
        value
        2.8
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Percent of CMV virus binding CD8+ t-cells at day +365 post-transplant
dispersion Type
Standard Error
groups
  1. description
    Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept. Abatacept: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
    id
    OG000
    title
    Abatacept
param Type
MEAN
reporting Status
POSTED
time Frame
Day +365 post-transplant
title
Protective Immunity
type
SECONDARY
unit Of Measure
percentage of total CD8+ t-cells

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice